GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Donor Stem Cells Be Rejected?

Yes. Your immune system can recognize donor stem cells as foreign and attack them. Matching the donor and using an appropriate transplant regimen reduce this risk, but do not guarantee acceptance [1]. The useful next question is which cells you mean: a blood stem cell transplant, donor mesenchymal stromal cells (MSCs), or tissue grown from induced pluripotent stem cells (iPS cells). Their immune risks cannot be reduced to one rejection percentage.

For context, a Swedish series of 967 first donor blood stem cell transplants reported 54 graft failures (5.6%), an outcome that is not identical to immune rejection [2]. A separate meta-analysis found that pre-existing donor-specific antibodies were associated with higher odds of primary graft failure (odds ratio 7.47), mainly in haploidentical and cord-blood transplantation. This is not a 7.47-fold increase in an individual’s absolute risk [3].

Can Donor Stem Cells Be Rejected?

What rejection means

Rejection is a host-versus-graft immune response: the recipient attacks the donor cells. In blood stem cell transplantation, conditioning treatment suppresses the recipient’s immunity and prepares for the graft, but remaining immune cells or pre-existing antibodies may still interfere with donor-cell acceptance [1][3].

Graft failure describes an unsuccessful graft outcome, not its cause. The Swedish study included loss of donor blood formation with recovery of the patient’s own blood-forming cells, called autologous reconstitution. This accounted for 43 of the 54 failures. Autologous reconstitution does not, by itself, establish or exclude immune rejection; the 5.6% figure must not be presented as a measured rejection rate [2].

Graft-versus-host disease (GVHD) runs in the opposite direction: donor immune cells attack the patient’s tissues. It can occur even after successful engraftment [1]. Human leukocyte antigens (HLA) are cell-surface markers used in donor matching. Even an HLA-matched graft can contain immune cells that recognize other differences, including minor histocompatibility antigens [4].

Donor-specific antibodies (DSA) target the donor’s HLA proteins. Pre-existing anti-HLA antibodies can follow pregnancy, transfusion, or a previous transplant. A positive DSA test identifies an immune risk; it does not alone prove that a graft is currently being rejected [3].

Acute GVHD affects about 30% to 50% of HLA-matched transplant recipients, with the exact rate depending on the graft source, the conditioning, and the prevention plan [5].

“The more HLAs that you and the donor have in common, the better the chance that your body will accept the donor’s stem cells.” — US National Cancer Institute [1]

How rejection differs by cell type

An allogeneic treatment uses donor cells; an autologous treatment uses your own cells. That distinction, explained in autologous versus allogeneic stem cells, comes before comparing immune risks. Donor MSCs have different immune properties from blood-forming grafts, and antibody findings in MSC studies do not supply a head-to-head rejection ranking across products [6][7].

Blood-forming stem cells

Blood-forming stem cells are given intravenously to rebuild blood production in conditions such as leukemia and marrow failure. Donor matching and transplant preparation are central to graft acceptance [1].

The Swedish cohort covered transplants performed in 1995–2010. Graft failure was associated with HLA mismatch (relative risk, RR, 7.64), removal of donor T cells outside the body (RR 8.82), non-malignant disease (RR 3.32), and reduced-intensity conditioning (RR 2.58). A total nucleated cell dose of at least 2.5 × 10⁸ cells/kg was associated with lower risk (RR 0.36). These are historical, single-center associations, not present-day risk estimates for every transplant. Among patients with malignant disease, five-year survival was 22% after graft failure versus 53% without it [2].

The DSA meta-analysis included 15 studies and 2,436 patients. Its pooled odds ratio for primary graft failure was 7.47 (95% confidence interval 4.54–12.28). The authors’ conclusion concerned haploidentical and cord-blood transplantation; an odds ratio cannot be converted into your probability of graft failure without a suitable baseline risk [3].

These blood-transplant figures do not estimate rejection after an MSC injection for knee joint disorders. Cell type, conditioning, dose, and treatment purpose differ.

Donor mesenchymal stromal cells

MSCs are studied and, for particular indications, used for their immune-modulating effects rather than to rebuild blood. They are not invisible to the immune system. HLA expression can change with inflammation, and preclinical studies show antibody responses and rejection of donor MSCs. Those animal findings explain a possible mechanism; they do not establish a human rejection rate [6].

A systematic review included 13 randomized trials with 555 participants, of whom 356 received donor MSCs. Its detailed results reported DSA in 32 of 214 patients assessed for that outcome (14.95%, about 15%). A different group was assessed using calculated panel-reactive antibody (cPRA), a broader sensitization measure. The combined 41 of 356 figure (11.51%) mixes these antibody measures; it is not a DSA-only rate or a clinical rejection rate. Diseases, injection routes, assays, and follow-up varied across the trials [7].

The review found no clear association between antibody findings and safety or tolerability in the included studies. That does not prove that antibodies are harmless or that they cannot affect benefit; the evidence was limited and the trials were not designed to establish a universal clinical rejection rate [7].

Many MSC studies have used donor cells without routine HLA matching [6]. Ryoncil in the United States and TEMCELL in Japan are donor bone marrow MSC products approved for acute GVHD. Their supporting studies involved post-transplant patients with inadequate steroid responses, not healthy recipients of elective infusions [8][9].

iPS-derived cells

iPS cells can be developed into specialized cells such as retinal pigment epithelium (RPE). Some donor-cell programs use HLA-homozygous bank lines, which carry two copies of the same HLA haplotype, to make matched grafts for multiple recipients [10].

A Japanese study published in 2020 followed five HLA-matched patients with wet age-related macular degeneration who received donor iPS-derived RPE cells beneath the retina. Pigmented areas consistent with graft cells were visible by six months and remained stable during the one-year observation period. The protocol used local steroids without systemic immunosuppressive medication [10].

One patient had a positive lymphocyte–graft immune reaction test followed by slight fluid recurrence; local steroid treatment resolved the suspected immune attack. Other suspected test responses were also reported without the same clinical picture. Five recipients cannot provide a reliable population rejection percentage. The small, uncontrolled study also reported other adverse events, including elevated eye pressure and steroid-related aseptic endophthalmitis, and cannot establish long-term safety or efficacy in other organs [10].

Separate mechanistic research identifies minor-antigen differences and natural killer (NK) cell responses as potential barriers even with HLA-homozygous donor lines. It does not establish which mechanism caused the eye-study reaction [11].

Donor cell product HLA matching Main immune risk
Blood-forming stem cells (bone marrow, peripheral blood, cord blood) Close HLA match is central; DSA testing for some patients Graft failure, which may or may not be immune
Mesenchymal stromal cells (bone marrow, fat, cord) Not routinely matched Donor-specific antibodies; clinical rejection is less clearly defined
iPS-derived cells Matching and immune treatment depend on the protocol Potential immune recognition despite matching; tissue-specific inflammation

What raises the risk

For a blood stem cell transplant, donor matching, graft composition, conditioning, and cell dose affect graft-failure risk. Ask your transplant center for results in patients with your disease and donor type rather than treating the historical figures above as your personal prognosis [2].

  • HLA mismatch. Donor–recipient HLA matching is important in blood stem cell transplantation; the acceptable match depends on the transplant approach [1].
  • Donor-specific antibodies. Old antibodies against the donor’s HLA can hit the graft. The worry grows when the antibody level is high and the donor is mismatched [3].
  • Prior pregnancy, transfusion, or transplant. These events can leave HLA antibodies behind. Mention them before the team picks a donor [3].
  • T-cell depletion of the graft. Removing donor T cells can reduce GVHD, but was associated with increased graft failure in the historical cohort [1][2].
  • Reduced-intensity conditioning. Gentler conditioning can leave more of your immune cells alive to fight the graft [2].
  • Low stem cell dose. In the 967-patient series, a higher total nucleated cell dose was linked to fewer graft failures [2].
  • Repeat donor MSC exposure. Do not assume that previous tolerance guarantees future tolerance. The MSC review did not establish a consistent relationship between dose count and antibody development; ask what immune monitoring the specific protocol uses [7].

What rejection looks like

After a blood stem cell transplant

Graft failure can look like low or sliding blood counts, tiredness, fever, infections, or bleeding. Your team watches blood counts and donor chimerism, and they may suggest a bone marrow biopsy. You cannot diagnose graft failure from how you feel alone. Often the transplant team spots it before you notice a clear change yourself [1][2].

Acute GVHD often shows up in the first three months: a rash, watery diarrhea, nausea, belly pain, or yellow eyes. Chronic GVHD can arrive later and touch skin, mouth, eyes, liver, lungs, and joints [1]. A new rash, diarrhea, or yellow eyes after a donor transplant needs same-day review. Do not tweak immunosuppressive drugs by yourself.

After a donor MSC infusion

Fever, chills, rash, breathlessness, or a drop in blood pressure during or after an infusion needs prompt medical assessment. These signs do not by themselves distinguish an infusion reaction, infection, or rejection. Product-specific risks matter when considering stem cell treatment safety in Japan; for example, infections and fever were among common adverse reactions reported for Ryoncil [8].

Disappointing benefit or new DSA does not alone diagnose MSC rejection. If a provider offers a “rejection blood test,” ask what it measures, how it was validated for that product, and which result would change treatment [7].

After an iPS-derived graft

The eye-study team combined eye examinations, imaging, and research immune testing rather than diagnosing rejection from symptoms alone [10]. For any tissue graft, get the study team’s monitoring schedule and contact instructions; eye findings cannot be used as a warning-sign checklist for heart or brain grafts.

How rejection is tested

Before a blood transplant, HLA typing assesses donor matching and DSA testing identifies antibodies directed against a potential donor [1][3]. Afterward, blood counts and chimerism—the proportion of blood cells originating from the donor versus the recipient—help assess engraftment. In the Swedish cohort, the graft-failure definition included more than 95% recipient cells after engraftment without relapse, or repeat transplantation for specified low blood counts [2].

For MSCs, antibody assays detect sensitization, not necessarily destruction of the cells or loss of clinical benefit. DSA and cPRA are not interchangeable tests. Any proposed testing plan should state the assay, baseline result, follow-up timing, and consequences of a positive finding [7].

For iPS-derived tissue, monitoring is protocol- and organ-specific. The published retinal study’s immune assay was a research method, not a general-purpose test predicting whether any donor-cell graft will last [10].

Prevention and treatment

For blood grafts, the transplant team weighs HLA matching, DSA, conditioning, cell dose, and immune suppression together. Changes that reduce one complication can affect another, including GVHD [1][2][3]. If graft failure occurs, the response depends on its cause, blood counts, and donor-cell recovery; some patients need another transplant [2].

For donor MSCs, do not assume that a blood-transplant matching or antibody-removal regimen applies. The reviewed MSC studies do not establish a universal HLA-matching or desensitization strategy to prevent clinical rejection [6][7]. Product quality and sterility are separate safety questions, not proof that cells cannot be rejected.

For iPS-derived tissue, follow the specific immune-treatment protocol. The retinal study’s use of local steroids does not establish that systemic immunosuppression can be avoided for other organs [10]. Do not start, stop, or adjust immune-suppressing medicines yourself.

What approvals say about rejection

Ryoncil and TEMCELL are approved to treat acute GVHD, not to make all donor-cell treatments rejection-proof [8][9].

The FDA approved Ryoncil in December 2024 for steroid-refractory acute GVHD in children aged two months and older. In its 54-patient single-arm study, the Day-28 overall response rate was 70% (95% confidence interval 56.4%–82.0%). Complete and partial response rates were reported as 30% and 41%, respectively; rounding explains why those figures sum to 71%. Median response duration was 54 days, measured from the Day-28 response to progression, new systemic GVHD treatment, or death. These are GVHD response outcomes, not donor-MSC survival or rejection outcomes [8].

Ryoncil is given intravenously, initially at 2 × 10⁶ MSCs/kg twice weekly for four weeks, with continuation based on response. Common reported adverse reactions included infections, fever, bleeding, edema, abdominal pain, and hypertension [8].

Japan approved TEMCELL in 2015 for acute GVHD after hematopoietic stem cell transplantation, with precautions specifying use after an inadequate steroid response. In the Japanese 25-patient open-label phase II/III study, 12 patients (48%) achieved a complete response lasting at least 28 days, and 15 (60%) were alive at 180 days. Follow-up extended to 52 weeks. The study had no concurrent control group [9].

TEMCELL study participants experienced adverse events including infections, anemia, and thrombotic microangiopathy. Events occurring after treatment are not automatically proof that the product caused them, particularly in severely ill transplant recipients [9].

Neither study was a head-to-head comparison between the products. Their results cannot establish efficacy for knee arthritis, Parkinson’s disease, spinal cord injury, or aging, nor predict tolerance in people outside these post-transplant populations [8][9].

Japan’s rules for donor-cell treatment

Japan runs two separate tracks: the ASRM, which covers regenerative medicine offered as medical care and sets rules for clinics, cell processing, and plan filing, and the PMD Act, which covers products sold on the market and brings PMDA review and approval [12][13].

A treatment offered through the ASRM framework is not thereby a marketing-approved regenerative medical product. The applicable review and legal requirements still have to be met; a filed plan alone proves neither efficacy nor freedom from rejection. Product approval is a separate process involving PMDA review and MHLW approval for a specified indication [12].

When discussing allogeneic stem cell therapy in Japan, ask which product, disease, and regulatory route the provider means. A discussion of registration and compliance should identify the actual plan or approval, not replace the underlying regulatory documents.

Questions to ask first

When choosing a stem cell hospital in Japan, bring the proposed product name and consent form, relevant pregnancy/transfusion/transplant history, and any existing HLA or antibody results. Ask for written answers tied to the product and indication before consenting or paying.

For example, if a provider describes a donor MSC infusion as “unmatched but rejection-free,” ask: “Which study tested this same product, by this route, in people with my condition? Did it measure antibodies, symptoms, cell persistence, or all three?” An antibody result and successful treatment are different outcomes [7].

  1. What exactly is being infused? Cell type, donor source, culture method, passage number, dose, and route. “Stem cells” alone is not enough.
  2. What is its regulatory status in Japan? Ask for the product’s marketing approval and approved indication, or the relevant ASRM plan and evidence for this particular use.
  3. Will you test HLA and anti-HLA antibodies? Which tests are relevant to this product, and what changes if DSA is present?
  4. What outcome will you measure, and when? Pain, function, imaging, blood counts, chimerism, or something else. Ask for results in people like you, not a testimonial.
  5. What happens if the graft fails or benefit fades? Ask who assesses the cause, manages complications, and coordinates any rescue treatment. A second transplant is a blood-graft question, not a routine remedy for an MSC infusion.
  6. Which complications apply to this cell product? Blood grafts require discussion of GVHD as well as graft failure. For MSCs or tissue grafts, ask about sensitization, infusion or procedure reactions, infection, and protocol-specific risks.
  7. What standard treatment might I delay? Review indications and contraindications with the treating clinician; do not substitute a website’s list for a product label or individual assessment.
  8. What is the total cost? A treatment-cost breakdown should separate consultation, cell processing, hospital care, follow-up, and possible complication costs.

For any proposed research treatment, a trial registration identifies the protocol; it is not proof that treatment works. Request the actual results, comparison group, follow-up period, and adverse-event record.

Questions about donor-cell treatment in Japan?

Ask about the proposed cell product, regulatory status, and consultation process before considering treatment. An inquiry does not establish medical suitability or guarantee acceptance of donor cells.

Contact us

Bottom line

Donor cells can provoke immune responses, but graft failure, DSA, and GVHD measure different things. None of these figures is a universal probability that your donor-cell treatment will be rejected.

Product or outcome Key number What it describes
Blood stem cell transplant 54/967 (5.6%) graft failure Swedish cohort, 1995–2010; outcome does not identify the immune mechanism [2]
Blood transplant with pre-existing DSA Odds ratio 7.47 for primary graft failure 15 studies, 2,436 patients; not a risk ratio or absolute probability [3]
Donor MSC treatment 32/214 (14.95%) developed DSA DSA-assessed subgroup of a 13-trial review; antibody development is not clinical rejection [7]
HLA-matched iPS-derived RPE One clinically suspected immune attack among five recipients Japanese wet-AMD study; other suspected test responses also occurred; not a population rate [10]
Acute GVHD (not rejection) 30%–50% HLA-matched allogeneic blood stem cell transplants [5]

Ask for a risk estimate matched to your product, disease, donor, and protocol. Continue prescribed care unless your treating clinician changes it. New fever, rash, diarrhea, or jaundice after a transplant warrants urgent contact with the transplant team; severe breathlessness, collapse, or a suspected serious allergic reaction needs emergency care.

This article provides general information, not a diagnosis or personal treatment recommendation.

Sources

Sources were initially consulted on 24 October 2026. Key study outcomes and regulatory statements were rechecked on 27 October 2026.

US National Cancer Institute. Stem Cell and Bone Marrow Transplants for Cancer. Patient education; allogeneic and autologous blood stem cell transplantation, HLA matching, GVHD. Accessed 24 October 2026.

Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48(4):537–543. Single-center Swedish cohort of 967 first allogeneic transplants, 1995–2010. doi:10.1038/bmt.2012.239.

Xie Y, Parekh J, Tang Z, Wu D, Wu X. Donor-Specific Antibodies and Primary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021;27(8):687.e1–687.e7. Fifteen studies, 2,436 patients; findings mainly in haploidentical and cord blood transplants. doi:10.1016/j.jtct.2021.04.030.

US National Cancer Institute. Complications, Graft-Versus-Host Disease, and Late Effects After Pediatric Hematopoietic Stem Cell Transplant (PDQ). Health professional version; updated 2 December 2024. GVHD biology, major and minor HLA disparities.

Aladağ E, Kelkitli E, Göker H. Acute Graft-Versus-Host Disease: A Brief Review. Turk J Haematol. 2020;37(1):1–4. Review of acute GVHD incidence, risk factors, and treatment. doi:10.4274/tjh.galenos.2019.2019.0157.

Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252–260. Review of preclinical and clinical evidence on MSC immunogenicity. doi:10.1038/nbt.2816.

Sanabria-de la Torre R, Quiñones-Vico MI, Fernández-González A, et al. Alloreactive Immune Response Associated to Human Mesenchymal Stromal Cells Treatment: A Systematic Review. J Clin Med. 2021;10(13):2991. Thirteen randomized trials, 555 participants, 356 treated with allogeneic MSCs. doi:10.3390/jcm10132991.

US Food and Drug Administration. FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients. Approval notification, 18 December 2024; single-arm study of 54 pediatric patients (NCT02336230).

Japan Pharmaceuticals and Medical Devices Agency. Report on the Deliberation Results: Temcell HS Inj.. September 2015. Allogeneic bone marrow-derived MSCs for acute GVHD after hematopoietic stem cell transplantation; Japanese phase II/III study, 25 patients (JR-031-301).

Sugita S, Mandai M, Hirami Y, et al. HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration. J Clin Med. 2020;9(7):2217. Five HLA-matched patients with wet AMD; one-year follow-up. doi:10.3390/jcm9072217.

Masuda K, Kawamoto H. Possible NK cell-mediated immune responses against iPSC-derived cells in allogeneic transplantation settings. Inflamm Regen. 2021;41:2. Review and in vitro data on HLA-homozygous iPSC-derived cells, minor antigens, and NK-cell KIR mismatch. doi:10.1186/s41232-020-00150-7.

Japan Pharmaceuticals and Medical Devices Agency. Regenerative Medical Products: Regulatory Framework. Explains the Act on the Safety of Regenerative Medicine and the PMD Act. Accessed 24 October 2026.

Japan Ministry of Health, Labour and Welfare. Act on the Safety of Regenerative Medicine (Act No. 85 of 2013), Japanese legal text. Accessed 24 October 2026. An English-language regulatory overview is available from the PMDA [12].